Lorlatinib is a potent tyrosine kinase inhibitor belonging to the anaplastic lymphoma kinase (ALK) inhibitor class, primarily indicated for the treatment of ALK-positive metastatic non-small-cell lung… Read more










Lorlatinib is a potent tyrosine kinase inhibitor belonging to the anaplastic lymphoma kinase (ALK) inhibitor class, primarily indicated for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC) in patients who have received prior therapies. To support rigorous pharmaceutical analysis, this category provides a comprehensive selection of high-quality reference standards, including the active pharmaceutical ingredient (API), related synthetic and degradative impurities, and relevant metabolites. Laboratories utilize these compounds to facilitate precise impurity profiling and method validation, ensuring compliance with strict regulatory quality control standards. Additionally, the inclusion of stable isotope labelled internal standards provides essential tools for accurate quantification and mass balance studies during complex analytical procedures. By offering these critical materials, researchers can maintain the integrity and reliability of their Lorlatinib development and stability testing programs.